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ABSTRACT 
The aim of this study was to determine the prevalence of extended-spectrum -
lactamase (ESBL)-producing Klebsiella pneumoniae isolated from urinary tract and 
bloodstream infections in a rural hospital in Manhiça, Mozambique. ESBLs were 
investigated among ceftriaxone-non-susceptible K. pneumoniae clinical isolates 
recovered between 2004 and 2009. Characterisation of blaCTX-M, blaSHV, blaOXA and 
blaTEM genes was performed by PCR and sequencing. Epidemiological relationships 
were established by phylogenetic analysis, repetitive extragenic palindromic PCR (rep-
PCR), pulsed-field gel electrophoresis (PFGE) and multilocus sequence typing (MLST), 
whilst plasmid transferability was evaluated by conjugation. In addition, the presence of 
class 1 and 2 integrons was studied. A total of 19 K. pneumoniae were analysed. The 
blaCTX-M-15 gene was found in all strains. Other ESBL genes were found concomitantly, 
including blaSHV-5, blaSHV-2, blaSHV-2A, blaSHV-12 and blaSHV-38. In addition, other -
lactamases such as blaTEM-1 and blaOXA-30 were also detected. rep-PCR identified 15 
different epidemiological profiles. MLST analysis also showed great variability of 
sequence types. The blaCTX-M-15 gene showed a high transfer capacity. The presence of 
class 1 integrons was high. High levels of multidrug resistance were also found. In 
conclusion, these data show the dominance of the CTX-M-type ESBL, particularly CTX-
M-15, supporting its worldwide dissemination, including in areas with limited access to 
third-generation cephalosporins. This finding is a matter of concern for clinical 
management as third-generation cephalosporins are an alternative for treating severe 
cases of multidrug-resistant infections in this community. 
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1. Introduction 
Infections caused by members of the Enterobacteriaceae family are among the major 
causes of hospital admission and associated mortality in children, particularly in 
developing countries of Africa [1]. Until recent years, infections caused by these micro-
organisms have been successfully treated with the available and inexpensive antibiotics 
present in these countries. However, the emergence and widespread development of 
multidrug-resistant (MDR) strains to the early effective antibiotics led to the introduction 
of broad-spectrum antibiotics such as fluoroquinolones or third-generation 
cephalosporins, which are often unaffordable or unavailable in most low-income 
countries [2]. Unfortunately, during the last three decades, extended-spectrum -
lactamases (ESBLs) produced by enteric pathogens have spread worldwide since their 
first description in 1983 [3]. 
 
The emergence and spread of ESBLs is an important public health problem and has 
had a tremendous impact, particularly in low-income countries. ESBL-producing micro-
organisms are also often resistant to other commonly available antibiotics, such as 
fluoroquinolones. Knowledge of the prevalence and characterisation of ESBLs is critical 
for defining local empirical strategies for the treatment of infections [4]. Although in 
Africa the presence of ESBLs has increasingly been reported [5–7], data in 
Mozambique remain limited. 
 
Klebsiella pneumoniae is among the most clinically relevant enterobacteria, being 
frequently reported as a cause of serious infections [3]. Moreover, an increase in the 
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isolation of MDR strains, especially those producing ESBLs, has also been described 
[3]. Infections caused by MDR K. pneumoniae strains have been associated with 
adverse clinical outcomes, including increased mortality, and prolonged hospitalisation 
associated with economic costs for the health system [8]. Here we characterise ESBL-
producing K. pneumoniae isolated from a rural hospital with limited access to third-
generation cephalosporins and broad-spectrum antibiotics in general in Southern 
Mozambique. 
 
2. Materials and methods 
2.1. Study population 
Klebsiella spp. strains from blood and urine isolated during the period August 2004 to 
December 2009 were retrospectively analysed for the presence of ESBLs. The study 
was conducted by the Centro de Investigação em Saúde de Manhiça (CISM) at 
Manhiça District Hospital, a rural referral hospital in Manhiça District, located 80 km 
north of Maputo, in Southern Mozambique. Bacterial infection surveillance in the 
paediatric population has been conducted in the study area since 1997. A description of 
the study area is given elsewhere [9]. Blood cultures were collected upon hospital 
admission from all children under 2 years of age and from older children up to 14 years 
of age with an axillary temperature ≥39 C or meeting the criteria of severe infection [1]. 
Urine samples were also collected in the same period among patients (adults and 
children) visiting the outpatient department or admitted to the wards with clinical 
suspicion of urinary tract infection (UTI). 
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2.2. Bacterial isolation 
Urine samples were cultured on MacConkey agar (Laboratorios CONDA, Madrid, 
Spain) and blood agar media (Becton Dickinson, Heidelberg, Germany). Blood culture 
bottles were incubated in an automated system (BACTEC® 9050; Becton Dickinson). 
Positive blood cultures were subcultured on solid media after Gram staining as 
appropriate. In both cases, pathogens were identified according to conventional 
microbiology protocols [10]. All selected Klebsiella spp. isolates were confirmed prior to 
analysis using matrix-assisted laser desorption/ionisation time-of-flight mass 
spectrometry (MALDI-TOF/MS) as described elsewhere [8]. 
 
2.3. Antimicrobial susceptibility testing 
Antimicrobial susceptibility testing was performed by a conventional disk diffusion 
method. The antimicrobial agents tested were: ampicillin (10 g); amoxicillin/clavulanic 
acid (20/10 g); cefoxitin (30 g); ceftriaxone (30 g); ceftazidime (30 g); imipenem (10 
g); meropenem (10 g); gentamicin (10 g); amikacin (30 g); tetracycline (30 g); 
chloramphenicol (30 g); trimethoprim/sulfamethoxazole (1.25/23.75 g); nalidixic acid 
(30 g); ciprofloxacin (5 g); rifampicin (5 g); and azithromycin (15 g). The category 
of resistance was interpreted according to Clinical and Laboratory Standard Institute 
(CLSI) guidelines [11]. Escherichia coli strain ATCC 25922 was used as a control. The 
breakpoints for rifampicin and azithromycin have not been established for Klebsiella 
Page 8 of 34
Ac
ce
pte
d M
an
us
cri
pt
 7 
spp., therefore resistance to azithromycin and rifampicin was considered as an inhibition 
halo diameter of ≤15 mm [12]. 
 
2.4. -Lactamase characterisation 
Klebsiella pneumoniae isolates showing intermediate or full resistance to ceftriaxone 
were phenotypically screened for the production of ESBLs by the double-disk synergy 
test. The presence of ESBL genes (blaCTX-M, blaSHV, blaOXA and blaTEM genes) was 
established by PCR using previously described conditions [13]. The presence of the 
insertion sequence ISEcp1 upstream of blaCTX-M-15 was determined by PCR as 
previously reported [14]. The amplified genes were sequenced by Macrogen DNA 
Sequencing Service (Macrogen, Seoul, South Korea). In addition, screening for metallo-
-lactamase (MBL) production was done by the imipenem/meropenem–ethylene 
diamine tetra-acetic acid (EDTA) combined disk test [15]. 
 
2.5. Genetic location and transferability studies 
To determine the genetic location of the genes encoding the different ESBLs, plasmids 
were extracted following the methodology of Kado and Liu [16]. The plasmid or 
chromosomal location of ESBL genes detected was determined by Southern blot using 
the ctx-m-1 probe. Transferability of the plasmids harbouring ESBLs was determined by 
conjugation using azide-resistant E. coli J53 as the recipient strain and all ESBL-
positive isolates as donor strains [17] using Muller–Hinton agar medium plus ceftriaxone 
(32 g/mL). The clonal relationship between donor strains, transconjugants and the J53 
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recipient strain was established by repetitive extragenic palindromic PCR (rep-PCR) 
[18]. Incompatibility groups of plasmids were identified in study strains and their 
transconjugants as previously described [19]. Co-transference of antibiotic resistance 
was determined in all positive transconjugants by disk diffusion methodology as 
previously described [11]. 
 
2.6. Integron study 
Strains were screened for the presence of class 1 and class 2 integrons by PCR using 
two sets of primers specific for the intI1 and intI2 genes [20]. The gene cassettes 
present within the variable regions of class 1 and class 2 integrons were determined by 
amplification with primers annealing to the 5' and 3' ends (5'-CS and 3'-CS) [20]. 
Amplified products were purified and sequenced at Macrogen. 
 
2.7. Molecular epidemiology study 
Klebsiella pneumoniae phylogenetic groups were established as described by Brisse et 
al. [21]. Clonal relationships were determined by rep-PCR as described elsewhere [18]. 
In all cases in which the identity was 80%, strains were analysed by pulsed-field gel 
electrophoresis (PFGE) [14]. 
 
PFGE profiles were compared using the fingerprinting software InfoQuestTM FP v.4.5 
(Bio-Rad, Hercules, CA). In order to construct dendrograms from the electrophoretic 
patterns, the Dice coefficient was used, with clustering by the unweighted pair-group 
Page 10 of 34
Ac
ce
pte
d M
an
us
cri
pt
 9 
method with arithmetic mean (UPGMA) with a 1% tolerance in band position 
differences. In addition, multilocus sequence typing (MLST) was performed using the 
sequences of the gapA, infB, mdh, pgi, phoE, rpoB and ton genes [22]. MLST 
sequences were compared on the Institut Pasteur website 
(http://www.pasteur.fr/recherche/genopole/PF8/mlst/Kpneumoniae.html) to obtain the 
sequence type (ST) profile. The MLST tree was built from the allelic profile t using the 
neighbour-joining method (http://pubmlst.org/analysis/). 
 
2.8. Statistical analysis 
Statistical analysis was performed using STATA software v.12.0 (Stata Corp., College 
Station, TX). Proportions were compared using the 2 or Fisher’s exact test, as 
appropriate. A P-value of <0.05 was considered significant. 
 
3. Results 
3.1. Study strains 
During the study period, Klebsiella spp. were identified as only 8.2% (30/368) and 25% 
(20/81) of the total Enterobacteriaceae isolated from blood and urine samples, 
respectively. A total of 19 ceftriaxone-resistant ESBL-producing K. pneumoniae isolates 
were included in this study, including 5 from urine samples (yielding a proportion of 26% 
of K. pneumoniae clinical isolates causing UTI), 11 from blood samples (proportion 
58%) and 3 strains (16%) from unspecified sources (Fig. 1). 
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3.2. Antimicrobial susceptibility 
The isolates were characterised as being dramatically resistant to the most commonly 
available antibiotics in this community. All of the isolates (100%) were resistant to 
ampicillin, cefoxitin, ceftriaxone, ceftazidime, chloramphenicol, gentamicin and 
rifampicin, 89% were resistant to amoxicillin/clavulanic acid and 
trimethoprim/sulfamethoxazole and 63% were resistant to tetracycline. Meanwhile, 
resistance levels to the remaining antimicrobial agents were lower; 32% of the isolates 
showed resistance to nalidixic acid and 16% showed resistance to amikacin, 
azithromycin and ciprofloxacin. No carbapenem-resistant isolates were found (Table 1). 
 
3.3. Identification of -lactamases by PCR and sequencing 
The blaCTX-M-15 gene was the most frequently detected, and ISEcp1 was found upstream 
of the blaCTX-M-15 gene in all cases except two. Other ESBL genes concomitantly 
detected were exclusively from the blaSHV family (blaSHV-2, blaSHV-2A, blaSHV-5, blaSHV-12 
and blaSHV-38), sometimes found in isolates carrying the blaCTX-M-15 gene. In addition, 
other -lactamases such as blaTEM-1 (84%; 16/19), blaOXA-30 (37%; 7/19) and different 
non-ESBL blaSHV-like genes (SHV-1, -11, -32, -33 and -121) were also detected. Analysis 
of the proportion of ESLBs according to the source of infection showed that ESBL-
producing K. pneumoniae isolates were more prevalent in bloodstream strains 
compared with uropathogenic strains [11/30 (37%) vs. 5/20 (25%), respectively; P < 
0.05]. No MBLs were detected (Table 1). 
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3.4. Transferability study 
A total of 13 transconjugants were obtained, with the blaCTX-M-15 gene being present in 
all cases. The plasmid incompatibility groups amplified in the parental isolates were 
IncFIC, IncFrep, IncA/C, IncY, IncFIIA, IncFIB, IncHI1 and IncHI2, showing a high 
variability of plasmid groups in these isolates. Meanwhile, in only 2 of the 13 
transconjugants were the transferred incompatibility groups identified: IncA/C in the K4 
transconjugant and IncFrep and IncFIB in the K13 transconjugant (Table 2). In addition, 
in 5 cases in which the ESBL phenotype was transferred, no incompatibility group was 
detected either in the parental or transconjugant strains. 
 
3.5. Analysis of integrons 
Twelve strains (63%) harboured class 1 integrons. Eight isolates had an integron of ca. 
800 bp containing the gene cassettes dfrA7 and dfrA15 in three and five isolates, 
respectively, conferring resistance to trimethoprim. Five strains had an integron of 2000 
bp. The first contained dfrA5–ereA2 conferring resistance to trimethoprim and 
macrolides; three isolates had dfrA16–aadA2; and the last had dfrA17–aadA5, both 
conferring resistance to trimethoprim and streptomycin–spectinomycin, respectively. It is 
important to highlight that two types of gene cassettes (dfrA15 and dfrA16–aadA2) were 
present in one strain (Table 1). No class 2 integrons were found. 
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3.6. Molecular epidemiological analysis 
Restriction fragment length polymorphism analysis of PCR-amplified fragments (PCR-
RFLP) of the gyrA gene showed that all K. pneumoniae isolates belonged to the same 
phylogenetic group (KpI). rep-PCR showed 15 different epidemiological profiles 
(considering the same profile as having ≥80% similarity), with a maximum of three 
isolates per profile, suggesting that most strains were not epidemiologically related, as 
shown by different strain clusters. This result was confirmed by PFGE, which showed 
that all isolates belonged to different clusters and thus no related profiles were found. 
MLST analysis also showed a large variability of ST groups as well as the emergence of 
a new ST group (gapA-2, infB-1, mdh-1, pgi-1, phoE-16, rpoB-4, tonB-12) (Fig. 2). The 
tree developed with allele variants also showed a high diversity of STs (Fig. 3). 
 
4. Discussion 
This study reports a high prevalence of ESBLs in Klebsiella isolates both in bacteraemia 
and UTIs. ESBL data in Klebsiella from Mozambique are scarce. In fact, only one study 
showed a high prevalence of ESBLs in the Central region (Beira City) for both Klebsiella 
spp. (75–100%) and E. coli (63.6–66.7%) causing UTI in children admitted to the 
malnutrition and paediatric wards [6]. 
 
The high prevalence of antibiotic resistance is a matter of special concern as antibiotic 
therapies are often instituted empirically in the country as well as due to the lack of 
available second-line alternatives [2,23]. The rates of ESBLs and antibiotic resistance 
observed in this study may be associated with a complex scenario of treatments derived 
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from the high prevalence of infectious diseases [tuberculosis (TB), malaria, human 
immunodeficiency virus (HIV), etc.] [24,25]. Therefore, bacteria present in the area are 
under direct pressure from trimethoprim/sulfamethoxazole not only in people treated 
with trimethoprim/sulfamethoxazole or sulfadoxine/pyrimethamine, but also in HIV-
infected and HIV-exposed subjects. In addition, there is high rifampicin pressure due to 
its use in the treatment of TB. In this line of thought, the analysis of integrons has shown 
the high number and variability of trimethoprim resistance genes. A serious parallel 
event is that trimethoprim/sulfamethoxazole pressure could co-select other resistance 
genes such as the ereA gene that confers resistance to macrolides. In the future, this 
fact may compromise the use of macrolides in the area. In addition, co-selection of 
resistance to antibiotics not in use in the area cannot be ruled out. 
 
All of the isolates in this study were related to the KpI phylogenetic group, in accordance 
with the idea that this group is the most common in clinical specimens and is related to 
highest levels of resistance. Thus, the high prevalence of KpI isolates could be a 
consequence of the high resistance rates, since antibiotic resistance is a critical 
parameter for the transmission of this pathogen [21]. The lack of clonality of the studied 
strains in conjunction with high heterogeneity in the ST groups shows the presence of 
non-related ESBL-producing MDR K. pneumoniae strains circulating in the community. 
The finding of blaCTX-M-15 as the most prevalent ESBL in this community confirms its 
important dissemination worldwide. In addition, five ESBLs belonging to the blaSHV 
group were detected. These blaSHV genes might be plasmid-encoded and then, due to 
the universal nature of the used primers, be co-amplified with the chromosomal blaSHV 
Page 15 of 34
Ac
ce
pte
d M
an
us
cri
pt
 14 
but detected in a preferential manner because of the high copy number. However, all 
blaSHV detected in the present study were unable to conjugate, thus the possible 
presence in the area of K. pneumoniae carrying different chromosomal blaSHV variants 
cannot be excluded. In fact, some of them, such as blaSHV-38, have been previously 
described as encoded on the chromosome of K. pneumoniae [26]. 
 
Although ESBLs have been previously reported in sub-Saharan Africa [5–7,27–30], the 
report of ESBLs in a rural hospital with limited access to third-generation 
cephalosporins, such as in Manhiça, Mozambique, is relevant, suggesting again the co-
selection of antibiotic resistance genes. Despite access to third-generation 
cephalosporins being limited in this community, a high prevalence of -lactamase 
genes, such as blaTEM-like and blaOXA-like, has been reported in Shigella and Salmonella 
isolates in previous studies, reflecting of the high use of ampicillin in the area [23]. 
 
No MBLs were detected and no isolates were resistant to carbapenems. However, 
blaSHV-38 is able to hydrolyse imipenem [26], and the combination of blaCTX-M-15 or blaSHV-
12 plus loss of expression of OmpK35 and/or OmpK36 results in full resistant to 
carbapenems [31]; thus, the use of carbapenems in the area needs to be done with 
caution. 
 
These findings are of special concern since ceftriaxone is the main third-generation 
cephalosporin used in the area for severe infections by MDR pathogens. In addition, it 
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was the only antibiotic found to be effective in vitro for MDR E. coli strains with reduced 
susceptibility to fluoroquinolones [2]. 
 
The reported prevalence of ESBLs is high compared with that reported in neighbouring 
countries such as Tanzania [27] and South Africa [5]. In another sub-Saharan country 
(Ethiopia), a high level of ESBL-producers (36%; 46% among inpatients and 33% 
among outpatients) was reported among E. coli strains from different samples (urine, 
sputum, stool, wound swabs) [28]. Similarly, ESBLs were found in 247 (27%) of 912 E. 
coli isolates, mainly blaCTX-M-14 (29%) and blaCTX-M-15 (24%), in hospital- and community-
acquired infections in Kenya, whilst non-ESBLs were found in 30% (54% blaTEM-1, 35% 
blaSHV-1 and 11% both blaTEM-1 and blaSHV) [29]. ESBLs have also been detected in 
Gabon, where 49.4% of all K. pneumoniae were ESBL-producers [7]. 
 
The ESBLs isolated from the bloodstream are likely to be community-acquired since 
blood cultures were collected upon admission and no extra blood cultures were taken 
during hospitalisation. Moreover, data from the demographic and morbidity databases 
showed that none of the patients in whom ESBL-producing micro-organisms were 
isolated had been hospitalised in the preceding 6 months. In contrast, we cannot rule 
out hospital-acquired ESBLs for those detected in urine since some samples were 
collected 48 h after admission. 
 
The community is predominately rural; non-prescribed antibiotic use is uncommon and 
third-generation cephalosporins are rarely used even in the hospital owing to their 
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limited availability. One plausible explanation for the high prevalence of ESBLs reported 
here is their possible association with international dissemination through the 
introduction of strains harbouring ESBLs and posterior dissemination within the 
community. Moreover, ESBL maintenance in the bacterial population may be due to the 
high levels of use of ampicillin or by co-selection related to the presence in the same 
genetic structure of mechanisms of resistance for other non-related antimicrobial agents 
used in the area. In this line of thought, carriage of blaCTX-M-15-producing E. coli isolates 
was reported in children living in a remote village with no data known of antibiotic 
exposure [30]. These data agree with the current massive spread of ESBLs worldwide. 
 
Treatment of infections caused by ESBL-producing organisms is difficult because of 
their resistance to other antibacterial agents, including fluoroquinolones. On the other 
hand, antibiotics used as second-line treatment such as carbapenems, which are still 
effective in vitro in the Manhiça area, are not available in most developing countries. 
Use of fluoroquinolones could be compromised in areas with a high prevalence of 
malaria that use chloroquine as treatment owing to the selection of quinolone resistance 
during antimalarial therapy in the absence of quinolone exposure [32], although, 
actually, in Manhiça chloroquine is not in use. 
 
The availability of effective antibiotics is a challenge, with this fact being of special 
concern in developing countries where the antibiotic armamentarium is limited. Steadily 
increasing resistance among Gram-negative bacteria associated with the emergence 
and spread of MDR strains including ESBL-producers is an important public health 
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problem with serious implications in low-income countries, which bear 95% of the global 
infectious disease burden and in which the use of empirical antimicrobial treatment 
plays a strategic role to counteract these diseases. This has resulted in many once 
easily curable infectious diseases becoming untreatable [7]. 
 
The present data are important to guide empirical treatment in the area and 
compromise the use of third-generation cephalosporins. This study highlights the 
spread of different ESBLs in rural Mozambique, despite the low levels of cephalosporin 
use, thereby demonstrating the need to establish antimicrobial resistance surveillance 
within the country to monitor the trends and new types of resistance mechanisms in 
order to promote adequate therapeutic guidelines. 
 
Acknowledgments: The authors thank all of the clinical and laboratory staff for their 
contribution in different stages of the study. Special thanks to the bacteriology 
laboratory technicians for their excellent support in performing antimicrobial 
susceptibility testing and ESBL phenotyping. The authors are also grateful to Donna 
Pringle for language correction. 
 
Funding: This work was supported by ‘Agencia Española de Cooperación Internacional 
y Desarrollo (AECID)’ (CISM receives core funding) and the Spanish Network for the 
Research in Infectious Diseases [REIPI RD12/0015]. JR has a fellowship from program 
I3 of the ISCIII [grant no. CES11/012]. MJP receives a ‘beca d’estada a l’estranger’ 
AGAUR, Generalitat de Catalunya. 
Page 19 of 34
Ac
ce
pte
d M
an
us
cri
pt
 18 
 
Competing interests: None declared. 
 
Ethical approval: Not required. 
Page 20 of 34
Ac
ce
pte
d M
an
us
cri
pt
 19 
References 
[1] Sigaúque B, Roca A, Mandomando I, Morais L, Quintó L, Sacarlal J, et al. 
Community-acquired bacteremia among children admitted to a rural hospital in 
Mozambique. Pediatr Infect Dis J 2009;28:108–13. 
[2] Mandomando I, Sigauque B, Morais L, Espasa M, Vallès X, Sacarlal J, et al. 
Antimicrobial drug resistance trends of bacteremia isolates in a rural hospital in 
Southern Mozambique. Am J Trop Med Hyg 2010;83:152–7. 
[3] Downie L, Armiento R, Subhi R, Kelly J, Clifford V, Duke T. Community-acquired 
neonatal and infant sepsis in developing countries: efficacy of WHO’s currently 
recommended antibiotics—systematic review and meta-analysis. Arch Dis Child 
2013;98:146–54. 
[4] Tumbarello M, Sali M, Trecarichi EM, Leone F, Rossi M, Fiori B, et al. 
Bloodstream infections caused by extended-spectrum--lactamase-producing 
Escherichia coli: risk factors for inadequate initial antimicrobial therapy. 
Antimicrob Agents Chemother 2008;52:3244–52. 
[5] Usha G, Chunderika M, Prashini M, Willem SA, Yusuf ES. Characterization of 
extended-spectrum -lactamases in Salmonella spp. at a tertiary hospital in 
Durban, South Africa. Diagn Microbiol Infect Dis 2008;62:86–91. 
[6] van der Meeren BT, Chhaganlal KD, Pfeiffer A, Gomez E, Ferro JJ, Hilbink M, et 
al. Extremely high prevalence of multi-resistance among uropathogens from 
hospitalised children in Beira, Mozambique. S Afr Med J 2013;103:382–6. 
Page 21 of 34
Ac
ce
pte
d M
an
us
cri
pt
 20 
[7] Alabi AS, Frielinghaus L, Kaba H, Kösters K, Huson MA, Kahl BC, et al. 
Retrospective analysis of antimicrobial resistance and bacterial spectrum of 
infection in Gabon, Central Africa. BMC Infect Dis 2013;13:455. 
[8] Berrazeg M, Diene SM, Drissi M, Kempf M, Richet H, Landraud L, et al. Biotyping 
of multidrug-resistant Klebsiella pneumoniae clinical isolates from France and 
Algeria using MALDI-TOF MS. PLoS One 2013;8:e61428. 
[9] Nhacolo AQ, Nhalungo DA, Sacoor CN, Aponte JJ, Thompson R, Alonso P. 
Levels and trends of demographic indices in southern rural Mozambique: 
evidence from demographic surveillance in Manhiça District. BMC Public Health 
2006;6:291. 
[10] Murray PR, Baron EJ, Jorgensen JH, Landry ML, Pfaller MA. Manual of 
clinical microbiology. 9th ed. Washington, DC: ASM Press; 2007. 
[11] Clinical and Laboratory Standards Institute. Performance standards for 
antimicrobial disk susceptibility tests; approved standard—tenth edition. 
Document M02-A10. Wayne, PA: CLSI; 2009. 
[12] Ochoa TJ, Ruiz J, Molina M, Del Valle LJ, Vargas M, Gil AI, et al. High 
frequency of antimicrobial drug resistance of diarrheagenic Escherichia coli in 
infants in Peru. Am J Trop Med Hyg 2009;81:296–301. 
[13] Jouini A, Vinue L, Slama KB, Sáenz Y, Klibi N, Hammami S, et al. 
Characterization of CTX-M and SHV extended-spectrum -lactamases and 
associated resistance genes in Escherichia coli strains of food samples in 
Tunisia. J Antimicrob Chemother 2007;60:1137–41. 
Page 22 of 34
Ac
ce
pte
d M
an
us
cri
pt
 21 
[14] Durmaz R, Otlu B, Koksal F, Hosoglu S, Ozturk R, Ersoy Y, et al. The 
optimization of a rapid pulsed-field gel electrophoresis protocol for the typing of 
Acinetobacter baumannii, Escherichia coli and Klebsiella spp. Jpn J Infect Dis 
2009;62:372. 
[15] Tsakris A, Poulou A, Pournaras S, Voulgari E, Vrioni G, Themeli-Digalaki 
K, et al. A simple phenotypic method for the differentiation of metallo--
lactamases and class A KPC carbapenemases in Enterobacteriaceae clinical 
isolates. J Antimicrob Chemother 2010;65:1664–71. 
[16] Kado CI, Liu ST. Rapid procedure for detection and isolation of large and 
small plasmids. J Bacteriol 1981;145:1365–73. 
[17] Pérez-Moreno MO, Picó-Plana E, de Toro M, Grande-Armas J, Quiles-
Fortuny V, Pons MJ, et al. -Lactamases, transferable quinolone resistance 
determinants, and class 1 integron-mediated antimicrobial resistance in human 
clinical Salmonella enterica isolates of non-Typhimurium serotypes. Int J Med 
Microbiol 2013;303:25–31. 
[18] Navia MM, Capitano L, Ruiz J, Vargas M, Urassa H, Schellemberg D, et 
al. Typing and characterization of mechanisms of resistance of Shigella spp. 
isolated from feces of children under 5 years of age from Ifakara, Tanzania. J 
Clin Microbiol 1999;37:3113–7. 
[19] Carattoli A, Bertini A, Villa L, Falbo V, Hopkins KL, Threlfall EJ. 
Identification of plasmids by PCR-based replicon typing. J Microbiol Methods 
2005;63:219–28. 
Page 23 of 34
Ac
ce
pte
d M
an
us
cri
pt
 22 
[20] Sáenz Y, Briñas L, Domínguez E, Ruiz J, Zarazaga M, Vila J, et al. 
Mechanisms of resistance in multiple-antibiotic-resistant Escherichia coli strains 
of human, animal, and food origins. Antimicrob Agents Chemother 
2004;48:3996–4001. 
[21] Brisse S, van Himbergen T, Kusters K, Verhoef J. Development of a rapid 
identification method for Klebsiella pneumoniae phylogenetic groups and 
analysis of 420 clinical isolates. Clin Microbiol Infect 2004;10:942–5. 
[22] Diancourt L, Passet V, Verhoef J, Grimont PA, Brisse S. Multilocus 
sequence typing of Klebsiella pneumoniae nosocomial isolates. J Clin Microbiol 
2005;43:4178–82. 
[23] Mandomando I, Jaintilal D, Pons MJ, Vallès X, Espasa M, Mensa L, et al. 
Antimicrobial susceptibility and mechanisms of resistance in Shigella and 
Salmonella isolates from children under five years of age with diarrhea in rural 
Mozambique. Antimicrob Agents Chemother 2009;53:2450–4. 
[24] González R, Munguambe K, Aponte J, Bavo C, Nhalungo D, Macete E, et 
al. High HIV prevalence in a southern semi-rural area of Mozambique: a 
community-based survey. HIV Med 2012;13:581–8. 
[25] World Health Organization. Global tuberculosis report 2013. Geneva, 
Switzerland: WHO; 2013. 
[26] Poirel L, Héritier C, Podglajen I, Sougakoff W, Gutmann L, Nordmann P. 
Emergence in Klebsiella pneumoniae of a chromosome-encoded SHV -
lactamase that compromises the efficacy of imipenem. Antimicrob Agents 
Chemother 2003;47:755–8. 
Page 24 of 34
Ac
ce
pte
d M
an
us
cri
pt
 23 
[27] Blomberg B, Jureen R, Manji KP, Tamim BS, Mwakagile DS, Urassa WK, 
et al. High rate of fatal cases of pediatric septicemia caused by Gram-negative 
bacteria with extended-spectrum -lactamases in Dar es Salaam, Tanzania. J 
Clin Microbiol 2005;43:745–9. 
[28] Mulualem Y, Kasa T, Mekonnen Z, Suleman S. Occurrence of extended 
spectrum -lactamases in multi-drug resistant Escherichia coli isolated from a 
clinical setting in Jimma University Specialized Hospital, Jimma, southwest 
Ethiopia. East Afr J Public Health 2012;9:58–61. 
[29] Kiiru J, Kariuki S, Goddeeris BM, Butaye P. Analysis of -lactamase 
phenotypes and carriage of selected -lactamase genes among Escherichia coli 
strains obtained from Kenyan patients during an 18-year period. BMC Microbiol 
2012;12:155. 
[30] Ruppe E, Woerther PL, Diop A, Sene AM, Da Costa A, Arlet G, et al. 
Carriage of CTX-M-15-producing Escherichia coli isolates among children living 
in a remote village in Senegal. Antimicrob Agents Chemother 2009;53:3135–7. 
[31] Tsai YK, Liou CH, Fung CP, Lin JC, Siu LK. Single or in combination 
antimicrobial resistance mechanisms of Klebsiella pneumoniae contribute to 
varied susceptibility to different carbapenems. PLoS One 2013;8:e79640. 
[32] Davidson RJ, Davis I, Willey BM, Rizg K, Bolotin S, Porter V, et al. 
Antimalarial therapy selection for quinolone resistance among Escherichia coli in 
the absence of quinolone exposure, in tropical South America. PLoS One 
2008;3:e2727. 
Page 25 of 34
Ac
ce
pte
d M
an
us
cri
pt
 24 
Fig. 1. Flowchart of Klebsiella isolates and the prevalence of extended-spectrum -
lactamases (ESBLs) in blood and urine samples. CRO, ceftriaxone. 
 
Fig 2. Epidemiological relationships between Klebsiella pneumoniae isolates. rep-PCR, 
repetitive extragenic palindromic PCR; ST, sequence type. 
 
Fig. 3. Tree of allelic profile using multilocus sequence typing (MLST) in Klebsiella 
pneumoniae isolates. 
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Highlights 
 We showed the dominance of the CTX-M-type extended-spectrum -lactamase 
(ESBL) in Mozambique, supporting its worldwide dissemination. 
 We report a high prevalence of ESBLs in Klebsiella isolates both in bloodstream 
and urinary tract infections. 
 We report the presence of ESBLs in an area with limited access to third-
generation cephalosporins. 
 Third-generation cephalosporins are an alternative for treating multidrug-resistant 
infections in Mozambique. 
 Rates of antibiotic resistance are very high. 
Edited Highlights
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Table 1 
Study strains, -lactamase analysis, resistance profile and class 1 integron characterisation 
Isolate Source ESBL 
genes 
Other -
lactamases 
genes 
ISEcp1 
upstream of 
CTX-M 
Antibiotic resistance 
pattern a 
Integron 
K1 Indeterminate CTX-M-15, 
SHV-5 
TEM-1 Absent AMP-AMC-CHL-GEN-
TET-RIF-SXT 
dfrA7 
K2 Indeterminate CTX-M-15 TEM-1, SHV-1 Present AMP-AMC-CHL-GEN-
TET-RIF-SXT-AZM 
dfrA15 
K4 Blood CTX-M-15 TEM-1, SHV-1 Present AMP-AMC-CHL-GEN-
TET-RIF-SXT 
dfrA5–ereA2 
K5 Blood CTX-M-15 TEM-1, SHV-33, 
OXA-30 
Present AMP-AMC-AMK-CHL-
GEN-TET-RIF-SXT 
– 
K6 Blood CTX-M-15, 
SHV-2 
TEM-1 Present AMP-AMC-CHL-GEN-
TET-RIF-SXT 
dfrA7 
K8 UTI CTX-M-15 TEM-1, SHV-121 Present AMP-AMC-CHL-GEN-
TET-RIF-SXT 
dfrA7 
K9 Blood CTX-M-15 TEM-1, SHV-11 Present AMP-AMC-CHL-GEN-
TET-RIF-SXT 
dfrA15/dfrA16–
aadA2 
K10 Indeterminate CTX-M-15 TEM-1, SHV-11, 
OXA-30 
Present AMP-AMC-CHL-GEN-
TET-RIF 
dfrA16–aadA2 
Edited Table 1
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K12 Blood CTX-M-15 TEM-1, SHV-1, 
OXA-30 
Present AMP-CHL-AMK-GEN-
RIF-SXT 
dfrA15 
K13 Blood CTX-M-15 TEM-1, SHV-32 Present AMP-AMC-CHL-GEN-
NAL-TET-RIF-SXT-
AZM 
dfrA17–aadA5 
K15 Blood CTX-M-15, 
SHV-38 
TEM-1, OXA-30 Present AMP-CHL-AMK-GEN-
RIF-SXT 
– 
K16 Blood CTX-M-15, 
SHV-2A 
TEM-1 Present AMP-AMC-CHL-GEN-
RIF-SXT 
dfrA15 
K18 UTI CTX-M-15, 
SHV-2 
– Present AMP-AMC-CHL-GEN-
RIF-SXT 
dfrA15 
K19 Blood CTX-M-15 TEM-1, SHV-11 Present AMP-AMC-CHL-GEN-
NAL-RIF-SXT 
– 
K24 UTI CTX-M-15 – Present AMP-AMC-CHL-GEN-
NAL-CIP-RIF-SXT 
– 
K25 Blood CTX-M-15 TEM-1, SHV-1, 
OXA-30 
Absent AMP-AMC-CHL-GEN-
NAL-CIP-TET-RIF-SXT 
dfrA16–aadA2 
K26 Blood CTX-M-15 – Present AMP-AMC-CHL-GEN-
NAL-RIF-SXT 
– 
K27 UTI CTX-M-15 TEM-1, SHV-11, 
OXA-30 
Present AMP-AMC-CHL-GEN-
TET-RIF-SXT-AZM 
– 
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K28 UTI CTX-M-15, 
SHV-12 
TEM-1, OXA-30 Present AMP-AMC-CHL-GEN-
NAL-CIP-TET-RIF-SXT 
– 
ESBL, extended-spectrum -lactamase; UTI, urinary tract infection; AMP, ampicillin; AMC, amoxicillin/clavulanic acid; 
CHL, chloramphenicol; GEN, gentamicin; TET, tetracycline; RIF, rifampicin; SXT, trimethoprim/sulfamethoxazole; AZM, 
azithromycin; AMK, amikacin; NAL, nalidixic acid; CIP, ciprofloxacin. 
a All isolates were additionally resistant to cefoxitin, ceftazidime and ceftriaxone. 
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Table 2 
Conjugation assay and plasmid characterisation 
Donor isolate Transconjugant 
Isolate Plasmid replicon  Plasmid replicon Co-selection of antibiotic resistance a ESBL gene 
K1 FIC – AMP-AMC-CHL-GEN-TET-RIF-SXT blaCTX-M-15 
K2 Frep    
K4 A/C A/C AMP-AMC-CHL-GEN-TET-RIF-SXT blaCTX-M-15 
K5 – –   
K6 – – AMP-AMC-CHL-GEN-TET-RIF-SXT blaCTX-M-15 
K8 A/C/Frep – AMP-AMC-CHL-GEN-TET-RIF-SXT blaCTX-M-15 
K9 Y    
K10 Y – AMP-AMC-CHL-GEN-TET-RIF blaCTX-M-15 
K12 FIIAs – AMP-CHL-AMK-GEN-RIF-SXT blaCTX-M-15 
K13 FIB/Frep FIB/Frep AMP-AMC-CHL-GEN-NAL-TET-RIF-SXT-AZM blaCTX-M-15 
K15 – – AMP-CHL-AMK-GEN-RIF-SXT blaCTX-M-15 
K16 – – AMP-AMC-CHL-GEN-RIF-SXT blaCTX-M-15 
K18 –    
K19 –    
K24 –    
K25 HI1, HI2 – AMP-AMC-CHL-GEN-NAL-CIP-TET-RIF-SXT blaCTX-M-15 
K26 – – AMP-AMC-CHL-GEN-NAL-RIF-SXT blaCTX-M-15 
Edited Table 2
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K27 Frep – AMP-AMC-CHL-GEN-TET-RIF-SXT-AZM blaCTX-M-15 
K28 – – AMP-AMC-CHL-GEN-NAL-CIP-TET-RIF-SXT blaCTX-M-15 
ESBL, extended-spectrum -lactamase; AMP, ampicillin; AMC, amoxicillin/clavulanic acid; CHL, chloramphenicol; GEN, 
gentamicin; TET, tetracycline; RIF, rifampicin; SXT, trimethoprim/sulfamethoxazole; AMK, amikacin; AZM, azithromycin; 
NAL, nalidixic acid; CIP, ciprofloxacin. 
a Bold letters indicate the antibiotic resistance phenotype that was found in the transconjugant strains. 
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rep-PCR profile 
group ST 
Phylogenetic 
group 
1 298 KpI 
2 45 KpI 
3 334 KpI 
4 111 KpI 
5 76 KpI 
6 626 KpI 
6 218 KpI 
6 218 KpI 
7 54 KpI 
8 ND KpI 
8 17 KpI 
8 101 KpI 
9 17 KpI 
10 29 KpI 
11 29 KpI 
12 29 KpI 
13 234 KpI 
14 268 KpI 
15 54 KpI 
Edited Figure 2
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